Sascha Gerdes

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5586673/publications.pdf

Version: 2024-02-01

98 papers	3,300 citations	201385 27 h-index	168136 53 g-index
123 all docs	123 docs citations	123 times ranked	4529 citing authors

#	Article	IF	Citations
1	Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task. European Journal of Cancer, 2019, 113, 47-54.	1.3	300
2	Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Annals of the Rheumatic Diseases, 2021, 80, 1306-1311.	0.5	289
3	A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task. European Journal of Cancer, 2019, 111, 148-154.	1.3	197
4	The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. British Journal of Dermatology, 2017, 176, 928-938.	1.4	155
5	Triptolide in the treatment of psoriasis and other immuneâ€mediated inflammatory diseases. British Journal of Clinical Pharmacology, 2012, 74, 424-436.	1.1	132
6	Adipokines and psoriasis. Experimental Dermatology, 2011, 20, 81-87.	1.4	126
7	Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses. Journal of Allergy and Clinical Immunology, 2020, 145, 1406-1415.	1.5	103
8	Smoking and Alcohol Intake in Severely Affected Patients with Psoriasis in Germany. Dermatology, 2010, 220, 38-43.	0.9	92
9	The genetic basis for most patients with pustular skin disease remains elusive. British Journal of Dermatology, 2018, 178, 740-748.	1.4	82
10	Leptin, adiponectin, visfatin and retinolâ€binding proteinâ€4 â€“ mediators of comorbidities in patients with psoriasis?. Experimental Dermatology, 2012, 21, 43-47.	1.4	78
11	Atopic dermatitis displays stable and dynamic skin transcriptome signatures. Journal of Allergy and Clinical Immunology, 2021, 147, 213-223.	1.5	76
12	Psoriasis: to treat or to manage?. Experimental Dermatology, 2014, 23, 705-709.	1.4	70
13	Multiple switches between <scp>GP</scp>2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaqueâ€type psoriasis: 30â€week results from the phase 3, confirmatory <scp>EGALITY</scp> study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 420-427.	1.3	70
14	Dimethylfumarate inhibits nuclear binding of nuclear factor ?B but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein ? in activated human T cells. British Journal of Dermatology, 2007, 156, 838-842.	1.4	69
15	Ustekinumab in the treatment of palmoplantar pustulosis. British Journal of Dermatology, 2010, 163, 1116-1118.	1.4	67
16	Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. British Journal of Dermatology, 2008, 159, 1116-23.	1.4	60
17	Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma. European Journal of Cancer, 2012, 48, 695-702.	1.3	55
18	Long-term Safety of Oral Systemic Therapies for Psoriasis: A Comprehensive Review of the Literature. Dermatology and Therapy, 2020, 10, 589-613.	1.4	49

#	Article	IF	Citations
19	Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 533-541.	1.3	47
20	Treatment outcomes with ixekizumab in patients with moderateâ€toâ€severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase <scp>III</scp> randomized studies. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 679-685.	1.3	46
21	Recommendations for detection of individual risk for comorbidities in patients with psoriasis. Archives of Dermatological Research, 2013, 305, 91-98.	1.1	44
22	Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. Dermatology and Therapy, 2020, 10, 431-447.	1.4	40
23	Cardiovascular biomarkers in patients with psoriasis. Experimental Dermatology, 2014, 23, 322-325.	1.4	39
24	Drug survival in the treatment of generalized pustular psoriasis: A retrospective multicenter study. Dermatologic Therapy, 2021, 34, e14814.	0.8	32
25	Prospective, Observational, Non-Interventional, Multicentre Study on the Efficacy and Tolerability of a New Calcipotriol/Betamethasone Aerosol Foam (EnstilarÂ®) in Patients with Plaque Psoriasis under Daily Practice Conditions. Dermatology, 2017, 233, 425-434.	0.9	31
26	Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study â€“ 2012 â€“ 2015. PLoS ONE, 2019, 14, e0220108.	1.1	31
27	Topische Therapie bei Psoriasis vulgaris â€“ ein Behandlungspfad. JDDG - Journal of the German Society of Dermatology, 2019, 17, 3-14.	0.4	31
28	Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis. Journal of Dermatological Treatment, 2020, 31, 769-775.	1.1	31
29	Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life. Journal of Dermatological Treatment, 2020, 31, 470-475.	1.1	30
30	Protein-coding variants contribute to the risk of atopic dermatitis and skin-specific gene expression. Journal of Allergy and Clinical Immunology, 2020, 145, 1208-1218.	1.5	29
31	Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies. RMD Open, 2021, 7, e002008.	1.8	28
32	Small dense LDL cholesterol in human subjects with different chronic inflammatory diseases. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 1100-1105.	1.1	27
33	Palmoplantar pustulosis â€“ a cross-sectional analysis in Germany. Dermatology Online Journal, 2017, 23, .	0.2	26
34	Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients. Dermatology, 2022, 238, 615-619.	0.9	26
35	Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman. Acta Dermato-Venereologica, 2017, 97, 283-284.	0.6	24
36	S2k guidelines for the treatment of psoriasis in children and adolescents â€“ Short version part 2. JDDG - Journal of the German Society of Dermatology, 2019, 17, 959-973.	0.4	24

#	Article	IF	Citations
37	Guselkumab is superior to fumaric acid esters in patients with moderateâ€toâ€severe plaque psoriasis who are naive to systemic treatment: results from a randomized, activeâ€comparatorâ€controlled phase IIIb trial (POLARIS). British Journal of Dermatology, 2020, 183, 265-275.	1.4	24
38	Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker â€“ a retrospective multicenter study. Journal of Dermatological Treatment, 2021, 32, 878-882.	1.1	24
39	Realâ€world effectiveness of guselkumab in patients with psoriasis: Healthâ€related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial. Journal of Dermatology, 2021, 48, 1854-1862.	0.6	24
40	Patientsâ€™ and Physiciansâ€™ Preferences for Systemic Psoriasis Treatments: A Nationwide Comparative Discrete Choice Experiment (PsoCompare). Acta Dermato-Venereologica, 2018, 98, 200-205.	0.6	23
41	Oral Health in Patients with Psoriasisâ€”A Prospective Study. Journal of Investigative Dermatology, 2019, 139, 1237-1244.	0.3	22
42	Combination of adalimumab with traditional systemic antipsoriatic drugs â€“ a report of 39 cases. JDDG - Journal of the German Society of Dermatology, 2012, 10, 821-837.	0.4	20
43	Drug survival and reasons for drug discontinuation in palmoplantar pustulosis: a retrospective multicenter study. JDDG - Journal of the German Society of Dermatology, 2019, 17, 503-516.	0.4	20
44	Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 431-440.	1.3	20
45	Impact of Comorbidities on the Management of Psoriasis. Current Problems in Dermatology, 2009, 38, 21-36.	0.8	19
46	Wnt5a - a potential factor linking psoriasis to metabolic complications. Experimental Dermatology, 2014, 23, 439-440.	1.4	18
47	Systemic Treatment with Fumaric Acid Esters in Six Paediatric Patients with Psoriasis in a Psoriasis Centre. Dermatology, 2014, 229, 199-204.	0.9	18
48	S2k guidelines for the treatment of psoriasis in children and adolescents â€“ Short version part 1. JDDG - Journal of the German Society of Dermatology, 2019, 17, 856-870.	0.4	18
49	Long-Term Treatment with Fumaric Acid Esters in an 11-Year-Old Male Child with Psoriasis. Dermatology, 2011, 222, 198-200.	0.9	17
50	Adiponectin levels in a large pooled plaque psoriasis study population. Journal of Dermatological Treatment, 2020, 31, 531-534.	1.1	17
51	Treatment of acrodermatitis continua of Hallopeau: A case series of 39 patients. Journal of Dermatology, 2020, 47, 989-997.	0.6	17
52	Elevated NK-cell transcriptional signature and dysbalance of resting and activated NK cells in atopic dermatitis. Journal of Allergy and Clinical Immunology, 2021, 147, 1959-1965.e2.	1.5	17
53	Rare variant analysis in eczema identifies exonic variants in DUSP1, NOTCH4 and SLC9A4. Nature Communications, 2021, 12, 6618.	5.8	17
54	Blood transcriptome profiling identifies 2 candidate endotypes of atopic dermatitis. Journal of Allergy and Clinical Immunology, 2022, 150, 385-395.	1.5	17

#	Article	IF	Citations
55	Serum mast cell tryptase is not a useful marker for disease severity in psoriasis or atopic dermatitis. British Journal of Dermatology, 2009, 160, 736-740.	1.4	14
56	A multicentre openâ€label study of apremilast in palmoplantar pustulosis (APLANTUS). Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2045-2050.	1.3	13
57	Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE). Journal of Dermatological Treatment, 2021, 32, 883-893.	1.1	11
58	Baseline characteristics of patients with moderateâ€toâ€severe psoriasis according to previous systemic treatment exposure: the PROSE study population. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2548-2556.	1.3	10
59	Systemic Antipsoriatic Combination Therapy with Fumaric Acid Esters for Plaque-Type Psoriasis: Report on 17 Cases. Dermatology, 2015, 230, 119-127.	0.9	9
60	Cost-effectiveness of systemic treatments for moderate-to-severe psoriasis in the German health care setting. Archives of Dermatological Research, 2016, 308, 249-261.	1.1	9
61	Screening for depression in psoriasis patients during a dermatological consultation: A first step towards treatment. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1451-1461.	0.4	9
62	Characterization of the skin microbiota in bullous pemphigoid patients and controls reveals novel microbial indicators of disease. Journal of Advanced Research, 2023, 44, 71-79.	4.4	9
63	Switch of psoriasis therapy from a fumaric acid ester mixture to dimethyl fumarate monotherapy: Results of a prospective study. JDDG - Journal of the German Society of Dermatology, 2019, 17, 906-912.	0.4	8
64	Oral dimethyl fumarate induces changes within the peripheral neutrophil compartment of patients with psoriasis that are linked with skin improvement*. British Journal of Dermatology, 2021, 185, 605-615.	1.4	8
65	Realâ€world evidence from the nonâ€interventional, prospective, German multicentre <scp>PERSIST</scp> study of patients with psoriasis after 1â€‰year of treatment with guselkumab. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1568-1577.	1.3	8
66	Biosimilars in Dermatology â€“ theory becomes reality. JDDG - Journal of the German Society of Dermatology, 2018, 16, 150-160.	0.4	7
67	Continued treatment with secukinumab is associated with high retention or regain of response. British Journal of Dermatology, 2019, 182, 67-75.	1.4	7
68	Two questions may be enough â€“ screening for depression in patients with psoriasis: a multicenter study. JDDG - Journal of the German Society of Dermatology, 2020, 18, 1115-1125.	0.4	7
69	Biologic Treatment in Combination with Lifestyle Intervention in Moderate to Severe Plaque Psoriasis and Concomitant Metabolic Syndrome: Rationale and Methodology of the METABOLyx Randomized Controlled Clinical Trial. Nutrients, 2021, 13, 3015.	1.7	7
70	Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5â€year data from <scp>reSURFACE</scp> 1 and <scp>reSURFACE</scp> 2. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1774-1783.	1.3	7
71	Bacterial soft tissue infection in psoriasis despite induction of epidermal antimicrobial peptides. Experimental Dermatology, 2014, 23, 862-864.	1.4	6
72	Therapy of psoriasis during pregnancy and breastâ€feeding. JDDG - Journal of the German Society of Dermatology, 2022, 20, 653-683.	0.4	6

#	Article	IF	Citations
73	Calcipotriol/betamethasone dipropionate foam demonstrates comparable efficacy to clinical trial data in the real world, improves patient satisfaction and is costâ€effective. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 28-34.	1.3	5
74	Zonulin May Not be a Marker of Autoimmunity in Patients with Psoriasis. Acta Dermato-Venereologica, 2012, 92, 171-172.	0.6	4
75	Online weight-loss coaching for patients with psoriasis: results of a pilot study. British Journal of Dermatology, 2016, 174, 674-676.	1.4	4
76	052 Efficacy of ixekizumab in moderate-to-severe psoriasis patients who have or have not received prior biologic therapies: An integrated analysis of 3 phase 3 studies. Journal of Investigative Dermatology, 2016, 136, S169.	0.3	4
77	002 Switching treatments of etanercept biosimilar GP2015 with originator product does not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis. Journal of Investigative Dermatology, 2017, 137, S193.	0.3	4
78	Serum autoantibody reactivity in bullous pemphigoid is associated with neuropsychiatric disorders and the use of antidiabetics and antipsychotics: a large, prospective cohort study. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 2181-2189.	1.3	4
79	Drug Survival und GrÃ¼nde fÃ¼r einen Therapieabbruch bei Pustulosis palmoplantaris: Eine retrospektive multizentrische Studie. JDDG - Journal of the German Society of Dermatology, 2019, 17, 503-517.	0.4	3
80	ActiPso: definition of activity types for psoriatic disease: A novel marker for an advanced disease classification. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2027-2033.	1.3	3
81	Genetic Analysis of MPO Variants in Four Psoriasis Subtypes in Patients from Germany. Journal of Investigative Dermatology, 2021, 141, 2079-2083.	0.3	3
82	Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2). Journal of Drugs in Dermatology, 2021, 20, 880-887.	0.4	3
83	Biosimilars in der DermatologieÂâ€“ Theorie wird RealitÃt. JDDG - Journal of the German Society of Dermatology, 2018, 16, 150-162.	0.4	2
84	Profiles of psychosocial variables and dental status in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e586-e587.	1.3	2
85	Absolute Psoriasis Area and Severity Index as a valuable marker to determine initial treatment response in psoriasis patients treated with guselkumab in routine clinical care. Dermatologic Therapy, 2022, 35, e15193.	0.8	2
86	Measuring wellâ€being in psoriasis: psychometric properties of the <scp>WHO</scp>â€5 questionnaire. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	2
87	Follicular rash during therapy with erlotinib (Tarcevaï¿½). JDDG - Journal of the German Society of Dermatology, 2006, 4, 855-857.	0.4	1
88	Switching expensive drugs with frequently diminishing value. British Journal of Dermatology, 2017, 177, 338-339.	1.4	1
89	Consistency of response maintained across demographic subgroups of psoriasis patients treated with guselkumab for up to 3 years in the VOYAGE 1 and 2 trials. Journal of the American Academy of Dermatology, 2019, 81, AB38.	0.6	1
90	Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab. Dermatology Online Journal, 2020, 26, .	0.2	1

#	Article	IF	Citations
91	A new option on the horizon for the treatment of psoriasis: it is needed, but not at any price. British Journal of Dermatology, 2016, 174, 1183-1184.	1.4	0
92	When to switch biologics: some answers, but lots of questions too. British Journal of Dermatology, 2018, 178, 20-20.	1.4	0
93	368 The microbiota of atopic dermatitis lesions induces TSLP expression in a 3D skin equivalent. Journal of Investigative Dermatology, 2019, 139, S278.	0.3	0
94	The efficacy of secukinumab with continued use in the treatment of psoriasis. British Journal of Dermatology, 2020, 182, e22-e22.	1.4	0
95	Longâ€term efficacy: the new gold standard?. British Journal of Dermatology, 2021, 185, 1086.	1.4	0
96	Another antiâ€interleukin (<scp>IL</scp>)â€17 inhibitor: is there an advantage of blocking <scp>ILâ€17A</scp> and <scp>ILâ€17F</scp> ?. British Journal of Dermatology, 2022, 186, 603-604.	1.4	0
97	Put the ducks in a row - which biologic to use first?. British Journal of Dermatology, 2018, 179, 241-242.	1.4	0
98	Psoriasisâ€Therapie wÃhrend Schwangerschaft und Stillzeit. JDDG - Journal of the German Society of Dermatology, 2022, 20, 653-685.	0.4	0